Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 3/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17320460 | 0.77 | CHRNB2 (0.41) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL9012393 | 0.74 | APLNR (0.37) | APLNRCHRM2CHRM4CHRM3NAAA | |
| SCHEMBL24324078 | 0.72 | APLNR (0.42) | APLNRCHRM2CHRM4CHRM3NAAA | |
| SCHEMBL29483876 | 0.71 | CHRNB2 (0.36) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL2125725 | 0.71 | CHRNB2 (0.36) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL15440621 | 0.71 | CYP1A2 (0.37) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL13525515 | 0.69 | APLNR (0.36) | APLNR | |
| SCHEMBL9012263 | 0.69 | APLNR (0.35) | APLNR | |
| SCHEMBL19755158 | 0.67 | CHRNB2 (0.33) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 | |
| SCHEMBL21174558 | 0.67 | CHRNB2 (0.33) | CHRM2CHRM4CHRM3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190046530-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | KONSTANTOPOULOS KONSTANTINOS (US) | 2019-02-14 | — | — | US | disclosed |
| US-20160038485-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | TALALAY, PAUL | 2016-02-11 | — | — | US | disclosed |
| US-5589504-A | Treatment of newborn jaundice | CORNELL RESEARCH FOUNDATION, INC. (US) | 1996-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190046530-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | PTGS2, PTGES2, CCAR2 | APLNR 2470/4885CHRM2 3626/4885CHRM4 4393/4885 |
| US-20160038485-A1 | PHASE 2 INDUCERS AND RELATED SIGNALING PATHWAYS PROTECT CARTILAGE AGAINST INFLAMMATION, APOPTOSIS AND STRESS | PTGS2, PTGES2, CCAR2 | APLNR 2470/4885CHRM2 3626/4885CHRM4 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.